Fosun International’s Acadia Pharmaceuticals ACAD Stock Holding History

Fosun International’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-59,000	Closed	-$1.57M	–	301
2019 Q1	$1.57M	Sell	59,000 -116,000	-66%	-$2.71M	0.1%	120
2018 Q4	$2.7M	Sell	175,000 -34,000	-16%	-$660K	0.16%	69
2018 Q3	$4.56M	Buy	+209,000	New	+$3.29M	0.22%	55

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fosun International's ACAD Position: Q2 2019 in Review

Fosun International sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 59,000 shares — an estimated $1.57M sold.

Fosun International first reported a position in ACAD in Q3 2018 and held it in 3 quarters. The position peaked at $4.56M in Q3 2018. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

Fosun International reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Fosun International sold 59,000 Acadia Pharmaceuticals shares in Q2 2019, an estimated $1.57M.
Fosun International first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 3 quarters.
Fosun International's Acadia Pharmaceuticals position peaked at $4.56M in Q3 2018.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on Fosun International's 13F filing for Q2 2019, filed 12 Aug 2019.